+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome)



Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome)



Annals of Oncology 18(7): 1159-1164



Palmar-plantar erythrodysesthesia (PPE), also called hand-foot syndrome or hand-to-foot syndrome, is a distinctive and relatively frequent dermatologic toxic reaction associated with certain chemotherapeutic agents. Pegylated liposomal doxorubicin (PLD), a long-circulating formulation of doxorubicin in which doxorubicin hydrochloride is encapsulated within pegylated liposomes, is approved to treat patients with metastatic breast cancer, advanced ovarian cancer, and acquired immunodeficiency syndrome-related Kaposi's sarcoma. The incidence of PPE is increased in patients receiving PLD compared with conventional doxorubicin. In studies that utilized the currently approved dose of PLD (50 mg/m(2) every 4 weeks), approximately 50% of all patients receiving PLD experienced PPE, and approximately 20% experienced grade 3 PPE. The pathophysiology of PPE, as it occurs with any drug with which it is associated, is not well understood. Studies evaluating the development of PPE specifically associated with PLD have not fully elucidated the mechanism; however, data support the roles of drug excretion in sweat and local pressure as contributors. When PPE develops, clinical interventions with respect to altering PLD administration include dose reduction, less frequent dosing, and ultimately, drug withdrawal with several consequences on treatment efficacy. This article will review the available data regarding the etiology and potential management strategies of PPE associated with PLD.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 049880563

Download citation: RISBibTeXText

PMID: 17229768

DOI: 10.1093/annonc/mdl477


Related references

Pegylated Liposomal Doxorubicin-induced Palmar-plantar Erythrodysesthesia. Gynecology and Minimally Invasive Therapy 7(1): 44-45, 2018

Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia. Cancer ChemoTherapy and Pharmacology 44(4): 303-306, 1999

The use of cod liver oil by patients receiving pegylated liposomal doxorubicin is associated with a lack of severe palmar-plantar erythrodysesthesia. European Journal of Gynaecological Oncology 30(4): 387-388, 2009

Incidence of palmar-plantar erythrodysesthesia in pretreated and unpretreated patients receiving pegylated liposomal doxorubicin. Tumori 95(6): 687-690, 2010

Prevention of palmar-plantar erythrodysesthesia with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (SAKK 92/08). Breast 23(3): 244-249, 2015

Clinical risk factors of PEGylated liposomal doxorubicin induced palmar plantar erythrodysesthesia in recurrent ovarian cancer patients. Gynecologic Oncology 131(3): 683-688, 2014

Elevated body mass index does not increase the risk of palmar-plantar erythrodysesthesia in patients receiving pegylated liposomal doxorubicin. Gynecologic Oncology 103(1): 72-74, 2006

Pyridoxine as prophylactic therapy for palmar-plantar erythrodysesthesia associated with administration of pegylated liposomal doxorubicin (caelyx): a single-center experience. Oncology 73(3-4): 277-278, 2008

Overall quality of life (QoL) is not meaningfully affected by severity of pegylated liposomal doxorubicin (PLD)-associated palmar-plantar erythrodysesthesia (PPE) among women with metastatic breast cancer. Journal of Clinical Oncology 23(16_Suppl): 788-788, 2016

Risk factors for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia over time: assessment of monocyte count and baseline clinical parameters. Cancer ChemoTherapy and Pharmacology 76(5): 1033-1039, 2016

Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. Oncology 77(5): 257-271, 2010

Hand-foot syndrome (palmar-plantar erythrodysesthesia. Schweizerische Medizinische Wochenschrift 130(40): 1413-1416, 2000

Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg/m2 every 4 weeks in previously treated patients with metastatic breast cancer. Oncology 70(2): 141-146, 2006

Antineoplastic TherapyInduced Palmar Plantar Erythrodysesthesia (Hand-Foot) Syndrome. American Journal of Clinical Dermatology 1(4): 225-234, 2000

Cutaneous toxicity by ftorafur, hand-foot or palmar-plantar erythrodysesthesia syndrome. Revista Clinica Espanola 188(3): 165-166, 1991